BioPharmSignal logoBioPharmSignal

Biotech News

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

Fate Therapeutics (FATE)Fate TherapeuticsCompany update

SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease,

Related news

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

KYMRKymera2026-09-01 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

CGEMCullinan Therapeutics, Inc.2026-09-24 11:00 EST

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

TEVATeva Pharmaceutical Industries2026-09-18 20:30 EST

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

TEVATeva Pharmaceutical Industries2026-10-02 12:00 EST

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

CGEMCullinan Therapeutics, Inc.2026-09-21 16:00 EST

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

View all latest news

Fate Therapeutics

iPSC-Derived Cell Therapy Platform Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells. FT819 FT819 is an iPSC-derived CD19 CAR T-cell therapy for autoimmune disease. The platform is intended to provide standardized manufacturing and repeatable dosing without patient-specific...

Recent company news

FATEFate Therapeutics2026-10-02 11:00 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATEFate Therapeutics2026-10-02 11:00 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATEFate Therapeutics2026-10-01 11:00 EST

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

FATEFate Therapeutics2026-10-01 11:00 EST

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

FATEFate Therapeutics2026-09-25 11:00 EST

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

Stock data

Close
2.30 USD
Market cap
299.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States